My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 388

    1.

    Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.

    Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB.

    Diabetes. 2002 Feb;51(2):443-8.PMID: 11812753 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.

    Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, Henry RR.

    Metabolism. 2003 May;52(5):540-6.PMID: 12759881 [PubMed - indexed for MEDLINE]Related articles

    3.

    Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.

    Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR.

    Diabetes. 2002 Jan;51(1):30-6.PMID: 11756319 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes.

    Meyer MM, Levin K, Grimmsmann T, Perwitz N, Eirich A, Beck-Nielsen H, Klein HH.

    Diabetes. 2002 Sep;51(9):2691-7.PMID: 12196460 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.

    Diabetes. 1999 Dec;48(12):2414-21.PMID: 10580431 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

    Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3,4,5-(PO4)3 in muscle of diabetic subjects.

    Luna V, Casauban L, Sajan MP, Gomez-Daspet J, Powe JL, Miura A, Rivas J, Standaert ML, Farese RV.

    Diabetologia. 2006 Feb;49(2):375-82. Epub 2006 Jan 5.PMID: 16395615 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.

    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.

    Diabetes. 2000 Apr;49(4):633-9.PMID: 10871202 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

    Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.

    Diabetes. 2003 Aug;52(8):1943-50.PMID: 12882909 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.

    Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR.

    Diabetes. 2003 Mar;52(3):667-74.PMID: 12606507 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.

    Strowig SM, Avilés-Santa ML, Raskin P.

    Diabetes Care. 2002 Oct;25(10):1691-8.PMID: 12351463 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.

    Karlsson HK, Hällsten K, Björnholm M, Tsuchida H, Chibalin AV, Virtanen KA, Heinonen OJ, Lönnqvist F, Nuutila P, Zierath JR.

    Diabetes. 2005 May;54(5):1459-67.PMID: 15855334 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.

    Yokoyama I, Yonekura K, Moritan T, Tateno M, Momose T, Ohtomo K, Inoue Y, Nagai R.

    J Nucl Med. 2001 Jul;42(7):1005-10.PMID: 11438619 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.

    Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV.

    Diabetes. 2003 Aug;52(8):1926-34.PMID: 12882907 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.

    Ann Intern Med. 1998 Feb 1;128(3):176-85.PMID: 9454525 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Mechanism of troglitazone action in type 2 diabetes.

    Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI.

    Diabetes. 2000 May;49(5):827-31.PMID: 10905493 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies.

    Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, Kahn CR.

    Metabolism. 2000 Mar;49(3):400-10.PMID: 10726921 [PubMed - indexed for MEDLINE]Related articles

    18.

    Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction.

    Kim YB, Kotani K, Ciaraldi TP, Henry RR, Kahn BB.

    Diabetes. 2003 Aug;52(8):1935-42.PMID: 12882908 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle.

    Temofonte N, Sajan MP, Nimal S, Pastoor T, Fumero C, Casaubon L, Powe JL, Standaert ML, Farese RV.

    Diabetologia. 2009 Jan;52(1):60-4. Epub 2008 Oct 30.PMID: 18972094 [PubMed - indexed for MEDLINE]Related articles

    20.

    Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes.

    Kim YB, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB.

    J Clin Invest. 1999 Sep;104(6):733-41.PMID: 10491408 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity